APA

Brell J. M., Matin K., Evans T., Volkin R. L., Kiefer G. J., Schlesselman J. J., Dranko S., Rath L., Schmotzer A., Lenzner D. & Ramanathan R. K. (20090407). Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer. : Oncology.

Chicago

Brell Joanna M, Matin Khalid, Evans Terry, Volkin Robert L, Kiefer Gauri J, Schlesselman James J, Dranko Shelley, Rath Linda, Schmotzer Amy, Lenzner Diana and Ramanathan Ramesh K. 20090407. Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer. : Oncology.

Harvard

Brell J. M., Matin K., Evans T., Volkin R. L., Kiefer G. J., Schlesselman J. J., Dranko S., Rath L., Schmotzer A., Lenzner D. and Ramanathan R. K. (20090407). Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer. : Oncology.

MLA

Brell Joanna M, Matin Khalid, Evans Terry, Volkin Robert L, Kiefer Gauri J, Schlesselman James J, Dranko Shelley, Rath Linda, Schmotzer Amy, Lenzner Diana and Ramanathan Ramesh K. Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer. : Oncology. 20090407.